The aim of this study was to evaluate changes in quality-of-life following

treatment of primary axillary hyperhidrosis with Botulinum toxin A (BTX-A).

A mixed-methods study combining quantitative and qualitative approaches

was conducted in 36 patients treated with BTX-A at the Department of

Dermatology, Thai Nguyen National Hospital. Disease severity and quality of

life were assessed using the Hyperhidrosis Disease Severity Scale (HDSS),

Hyperhidrosis Disease-Specific Measures–Axillary (HDSM-Ax), and

HidroQoL before and after treatment. In-depth interviews were also conducted

with 10 patients to further explore changes in quality of life. After treatment,

the mean HDSS score decreased from 2.9 to 1.4, while the mean HDSM-Ax

score decreased by 16.4 points. A total of 91.7% of patients reported an

improvement in symptoms, and no patients reported worsening of their

condition. The proportion of patients reporting no body odor or only very mild

body odor reached 91.6%. The mean quality-of-life score increased from 4.9 to

8.2, with 72.2% of patients reporting that their quality of life was much